JP2012509273A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509273A5 JP2012509273A5 JP2011536585A JP2011536585A JP2012509273A5 JP 2012509273 A5 JP2012509273 A5 JP 2012509273A5 JP 2011536585 A JP2011536585 A JP 2011536585A JP 2011536585 A JP2011536585 A JP 2011536585A JP 2012509273 A5 JP2012509273 A5 JP 2012509273A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- nhc
- independently
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 239000002105 nanoparticle Substances 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 19
- 108091034117 Oligonucleotide Proteins 0.000 claims 17
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 9
- 230000000692 anti-sense effect Effects 0.000 claims 9
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 125000000547 substituted alkyl group Chemical group 0.000 claims 8
- 150000001412 amines Chemical class 0.000 claims 6
- 125000004405 heteroalkoxy group Chemical group 0.000 claims 6
- 150000002632 lipids Chemical class 0.000 claims 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- -1 cationic lipid Chemical class 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 108091023037 Aptamer Proteins 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 108700011259 MicroRNAs Proteins 0.000 claims 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000001588 bifunctional effect Effects 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 108060000903 Beta-catenin Proteins 0.000 claims 1
- 102000015735 Beta-catenin Human genes 0.000 claims 1
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 claims 1
- 102100039165 Heat shock protein beta-1 Human genes 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 108091027076 Spiegelmer Proteins 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 108010088665 Zinc Finger Protein Gli2 Proteins 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 102000001307 androgen receptors Human genes 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000000799 fusogenic effect Effects 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 150000002466 imines Chemical class 0.000 claims 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 0 *CC(C(*(CC*=C(C1)[*@]1C1C=CC(C(*(CCCCC(*)*)=C)=O)=CC1)=C)=O)=C Chemical compound *CC(C(*(CC*=C(C1)[*@]1C1C=CC(C(*(CCCCC(*)*)=C)=O)=CC1)=C)=O)=C 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11537808P | 2008-11-17 | 2008-11-17 | |
| US61/115,378 | 2008-11-17 | ||
| PCT/US2009/064730 WO2010057160A1 (en) | 2008-11-17 | 2009-11-17 | Releasable fusogenic lipids for nucleic acids delivery systems |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012509273A JP2012509273A (ja) | 2012-04-19 |
| JP2012509273A5 true JP2012509273A5 (https=) | 2012-12-27 |
Family
ID=42170408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536585A Ceased JP2012509273A (ja) | 2008-11-17 | 2009-11-17 | 核酸送達系のための放出可能融合性脂質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110223257A1 (https=) |
| EP (1) | EP2355799A4 (https=) |
| JP (1) | JP2012509273A (https=) |
| CN (1) | CN102215820A (https=) |
| CA (1) | CA2742846A1 (https=) |
| TW (1) | TW201021852A (https=) |
| WO (1) | WO2010057160A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3539572A1 (en) | 2005-08-24 | 2019-09-18 | ImmunoGen, Inc. | Process for preparing maytansinoid antibody conjugates |
| TW201021853A (en) * | 2008-11-17 | 2010-06-16 | Enzon Pharmaceuticals Inc | Releasable cationic lipids for nucleic acids delivery systems |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| BRPI1010620B8 (pt) | 2009-06-03 | 2021-05-25 | Immunogen Inc | métodos de conjugação |
| SG186085A1 (en) * | 2010-06-03 | 2013-01-30 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| US9205099B2 (en) | 2010-06-22 | 2015-12-08 | Dna Therapeutics | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
| RS58367B1 (sr) | 2011-03-29 | 2019-03-29 | Immunogen Inc | Priprema konjugata antitela i majtanzinoida jednostepenim postupkom |
| EP2527440A1 (en) | 2011-05-27 | 2012-11-28 | Institut Curie | Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia |
| EP2788006B1 (en) | 2011-12-07 | 2026-01-07 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| US10358680B2 (en) * | 2012-09-11 | 2019-07-23 | Duke University | Nano-plasmonic molecular probes for plasmonics coupling interference |
| WO2014055877A1 (en) | 2012-10-04 | 2014-04-10 | Immunogen, Inc. | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
| US10130711B2 (en) | 2013-06-19 | 2018-11-20 | The Regents Of The University Of California | Chemical structures for localized delivery of therapeutic agents |
| JP6527516B2 (ja) | 2013-12-03 | 2019-06-05 | ノースウェスタン ユニバーシティ | リポソーム粒子、前述のものを作製する方法及びその使用 |
| ES2880468T3 (es) | 2014-03-14 | 2021-11-24 | Univ California | Conjugados de TCO y métodos para el suministro de agentes terapéuticos |
| TWI665192B (zh) | 2014-05-28 | 2019-07-11 | 德商拜耳作物科學股份有限公司 | 製備二氫異唑衍生物之方法 |
| AU2015269412B2 (en) | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| WO2016028940A1 (en) | 2014-08-19 | 2016-02-25 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
| KR20170078843A (ko) | 2014-11-21 | 2017-07-07 | 노오쓰웨스턴 유니버시티 | 구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수 |
| JP6823067B2 (ja) | 2015-09-10 | 2021-01-27 | タンボ・インコーポレイテッド | 生体直交型組成物 |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| CN107951861B (zh) * | 2016-10-17 | 2020-12-01 | 南京绿叶制药有限公司 | 一种脂质纳米粒膜材料组合物 |
| CN107951862B (zh) * | 2016-10-17 | 2021-03-12 | 南京绿叶制药有限公司 | 一种抑制bcl-2的反义寡聚核酸的脂质纳米粒及其制备方法 |
| US10383952B2 (en) * | 2016-12-21 | 2019-08-20 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| ES2983582T3 (es) | 2017-04-07 | 2024-10-23 | Tambo Inc | Composiciones bioortogonales |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| JP2020526558A (ja) | 2017-07-13 | 2020-08-31 | ノースウェスタン ユニバーシティ | オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法 |
| AU2018359904B2 (en) * | 2017-11-06 | 2023-02-23 | Nitto Denko Corporation | Fusogenic compounds for delivery of biologically active molecules |
| US12319711B2 (en) | 2019-09-20 | 2025-06-03 | Northwestern University | Spherical nucleic acids with tailored and active protein coronae |
| US12378560B2 (en) | 2019-10-29 | 2025-08-05 | Northwestern University | Sequence multiplicity within spherical nucleic acids |
| EP4295917A3 (en) | 2020-08-07 | 2024-02-28 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| LU103379B1 (en) * | 2024-09-09 | 2026-03-09 | Re3B Therapeutics Ug I G | Serum-Protein Coated Fusogenic Lipid Particles For Targeted Drug Delivery |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5945408A (en) * | 1996-03-06 | 1999-08-31 | G.D. Searle & Co. | Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors |
| CA2289702C (en) * | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| US6794499B2 (en) * | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6841537B1 (en) * | 1998-04-22 | 2005-01-11 | Protiva Biotherapeutics Inc. | Combination therapy using nucleic acids and conventional drugs |
| US6169078B1 (en) * | 1998-05-12 | 2001-01-02 | University Of Florida | Materials and methods for the intracellular delivery of substances |
| US8137695B2 (en) * | 2006-08-18 | 2012-03-20 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
| US20030077829A1 (en) * | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
| US20070042983A1 (en) * | 2001-05-18 | 2007-02-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| US20050222064A1 (en) * | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| US7015349B2 (en) * | 2003-03-26 | 2006-03-21 | The Gillette Company | Reduction of hair growth |
| NZ592917A (en) * | 2003-09-15 | 2012-12-21 | Protiva Biotherapeutics Inc | Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates |
| EP1692107A4 (en) * | 2003-12-10 | 2008-10-29 | Nitromed Inc | NITROGEN OXIDE-RELATED PYRUVATE COMPOUNDS, COMPOSITIONS AND USE METHOD |
| WO2006007712A1 (en) * | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| WO2006086330A2 (en) * | 2005-02-08 | 2006-08-17 | Id Biomedical Corporation Of Quebec C.O.B. As Glaxosmithkline Biologicals North America | Pharmaceutical compositions |
| JP5042863B2 (ja) * | 2005-02-14 | 2012-10-03 | サーナ・セラピューティクス・インコーポレイテッド | 生物学的に活性な分子をデリバリーするための脂質ナノ粒子系組成物および方法 |
| US7404969B2 (en) * | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| WO2006096701A2 (en) * | 2005-03-07 | 2006-09-14 | Id Biomedical Corporation Of Quebec C.O.B. As Glaxosmithkline Biologicals North America | Pharmaceutical liposomal compositions |
| US7919466B2 (en) * | 2006-02-01 | 2011-04-05 | The Regents Of The University Of California | Lymphatic zip codes in tumors and pre-malignant lesions |
| US20070293449A1 (en) * | 2006-06-20 | 2007-12-20 | Nastech Pharmaceutical Company Inc. | Compositions and methods for delivery of double-stranded rna |
| US20080255234A1 (en) * | 2007-04-11 | 2008-10-16 | Zinpro Corporation | Rumen protected lysine |
| CA2686735A1 (en) * | 2007-05-04 | 2008-11-13 | Mdrna, Inc. | Amino acid lipids and uses thereof |
-
2009
- 2009-11-17 CA CA2742846A patent/CA2742846A1/en not_active Abandoned
- 2009-11-17 WO PCT/US2009/064730 patent/WO2010057160A1/en not_active Ceased
- 2009-11-17 US US13/129,546 patent/US20110223257A1/en not_active Abandoned
- 2009-11-17 EP EP09826954A patent/EP2355799A4/en not_active Withdrawn
- 2009-11-17 CN CN2009801459159A patent/CN102215820A/zh active Pending
- 2009-11-17 TW TW098138943A patent/TW201021852A/zh unknown
- 2009-11-17 JP JP2011536585A patent/JP2012509273A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012509273A5 (https=) | ||
| JP2012509272A5 (https=) | ||
| JP2012509366A5 (https=) | ||
| JP2025181861A5 (https=) | ||
| CN113993839B (zh) | 一种可离子化脂质分子、其制备方法及其在制备脂质纳米颗粒中的应用 | |
| JP2011529912A5 (https=) | ||
| JP2012509258A5 (https=) | ||
| CA2767129C (en) | Compositions and methods for silencing apolipoprotein b | |
| AU2010248239B2 (en) | siRNA conjugate and preparation method thereof | |
| AU2012318249B2 (en) | Compositions and methods for silencing aldehyde dehydrogenase | |
| EP2796150B1 (en) | Novel oligonucleotide conjugates and use thereof | |
| RU2018113459A (ru) | Фармацевтическая композиция, содержащая анионное лекарственное средство, и способ ее получения | |
| KR101752812B1 (ko) | 고효율 나노입자형 이중나선 올리고 rna 구조체 및 그의 제조방법 | |
| JP2012509066A5 (https=) | ||
| KR101862349B1 (ko) | 개선된 고효율 나노입자형 올리고뉴클레오타이드 구조체 및 그의 제조방법 | |
| CA2963271A1 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| WO2007056861A1 (en) | Sirna silencing of influenza virus gene expression | |
| US9035039B2 (en) | Compositions and methods for silencing SMAD4 | |
| RU2016103695A (ru) | СВЯЗАННАЯ С РЕСПИРАТОРНЫМ ЗАБОЛЕВАНИЕМ ГЕН-СПЕЦИФИЧЕСКАЯ миРНК, ДВУСПИРАЛЬНАЯ КОНСТРУКЦИЯ ОЛИГО-РНК, СОДЕРЖАЩАЯ миРНК, И СОДЕРЖАЩАЯ ЕЕ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ ЛЕЧЕНИЯ РЕСПИРАТОРНОГО ЗАБОЛЕВАНИЯ | |
| KR101241852B1 (ko) | ｓｉＲＮＡ 접합체 및 그 제조방법 | |
| KR20120119212A (ko) | ｓｉＲＮＡ 접합체 및 그 제조방법 | |
| JP6051758B2 (ja) | ジアシルグリセロールと結合した分岐型ポリエチレングリコール、その製造方法およびポリエチレングリコール修飾リポソーム | |
| Kim et al. | Antiviral efficacy of a short PNA targeting microRNA-122 using galactosylated cationic liposome as a carrier for the delivery of the PNA-DNA hybrid to hepatocytes | |
| CN120398741A (zh) | 一种用于递送核酸物质的脂肪酸衍生物及其合成方法 | |
| RU2020142571A (ru) | Специфичные для гена амфирегулина двухцепочечные олигонуклеотиды и содержащие их композиции для профилактики и лечения связанных с фиброзом заболеваний и респираторных заболеваний |